Johnson & Johnson
NYSE: JNJ
$160.88
-$2.79 (-1.7%)
Closing Price on October 25, 2024
JNJ Articles
Where will the most brilliant investor in the world put his money if the markets collapse? Perhaps into some of the safe harbor stocks he already holds.
Published:
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
Published:
Stockcharts.comLong-term investors always look for companies that show signs that they will be around for a while. Membership on the Dividend Aristocrats list gives indication of longevity. In order...
Published:
July 17, 2thinkstock015: Markets opened mixed on Friday as the Nasdaq traded higher right from the opening bell and the Dow traded lower from opening to closing. Google shares rose to a new high of...
Published:
Last Updated:
A new report from UBS includes changes to the firm's Dividend Ruler stocks portfolio. Also featured are the current four top-yielding Dividend Ruler stocks.
Published:
Johnson & Johnson reported better-than-expected second-quarter financial results before the markets opened Tuesday.
Published:
Johnson & Johnson is expected to report its second-quarter financial results Tuesday morning before the markets open.
Published:
Earnings season for the second quarter of the calendar year has kicked off, and 24/7 Wall St. has put together a preview of some of the Dow Jones companies that are reporting their quarterly results...
Published:
With the Greek debacle throwing some very cold water on the market, it makes sense for investors to use cash wisely and scale into these stocks.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Published:
thinkstockJune 18, 2015: Markets opened higher on Thursday based on the FOMC’s decision to leave interest rates alone and generally good economic data reported early this morning. A weaker dollar...
Published:
Last Updated:
Older Americans, in many cases, have lost their tolerance for financial risk and they want to protect the size of the nest eggs they have put aside for retirement.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
The jump in market volatility did not deter executives and 10% shareholders this week, and insider buying stayed solid.
Published:
It turns out that Buffett has five public stocks that used to be far larger stakes or which seem like token positions.
Published: